Literature DB >> 32602788

A tool with many applications: vesicular stomatitis virus in research and medicine.

Altar M Munis1,2, Emma M Bentley3, Yasuhiro Takeuchi2,4.   

Abstract

INTRODUCTION: Vesicular stomatitis virus (VSV) has long been a useful research tool in virology and recently become an essential part of medicinal products. Vesiculovirus research is growing quickly following its adaptation to clinical gene and cell therapy and oncolytic virotherapy. AREAS COVERED: This article reviews the versatility of VSV as a research tool and biological reagent, its use as a viral and vaccine vector delivering therapeutic and immunogenic transgenes and an oncolytic virus aiding cancer treatment. Challenges such as the immune response against such advanced therapeutic medicinal products and manufacturing constraints are also discussed. EXPERT OPINION: The field of in vivo gene and cell therapy is advancing rapidly with VSV used in many ways. Comparison of VSV's use as a versatile therapeutic reagent unveils further prospects and problems for each application. Overcoming immunological challenges to aid repeated administration of viral vectors and minimizing harmful host-vector interactions remains one of the major challenges. In the future, exploitation of reverse genetic tools may assist the creation of recombinant viral variants that have improved onco-selectivity and more efficient vaccine vector activity. This will add to the preferential features of VSV as an excellent advanced therapy medicinal product (ATMP) platform.

Entities:  

Keywords:  Gene therapy; VSV; immune response; lentivirus; oncolytic virotherapy; pseudotype; vaccine; viral vector

Year:  2020        PMID: 32602788     DOI: 10.1080/14712598.2020.1787981

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  9 in total

1.  Dynamic Actin Filament Traps Mediate Active Diffusion of Vesicular Stomatitis Virus Ribonucleoproteins.

Authors:  Steven J Moran; Shelby Puckett; David A Ornelles; Jed C Macosko; George Holzwarth; Douglas S Lyles
Journal:  J Virol       Date:  2022-09-22       Impact factor: 6.549

2.  Serum extracellular vesicles for delivery of CRISPR-CAS9 ribonucleoproteins to modify the dystrophin gene.

Authors:  Nathalie Majeau; Annabelle Fortin-Archambault; Catherine Gérard; Joël Rousseau; Pouiré Yaméogo; Jacques P Tremblay
Journal:  Mol Ther       Date:  2022-05-26       Impact factor: 12.910

Review 3.  Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses.

Authors:  Anne Everts; Melissa Bergeman; Grant McFadden; Vera Kemp
Journal:  Biomedicines       Date:  2020-11-05

Review 4.  Lentiviral Vector Bioprocessing.

Authors:  Christopher Perry; Andrea C M E Rayat
Journal:  Viruses       Date:  2021-02-09       Impact factor: 5.048

5.  Population Variability Generated during Rescue Process and Passaging of Recombinant Mumps Viruses.

Authors:  Anamarija Slović; Tanja Košutić-Gulija; Dubravko Forčić; Maja Šantak; Maja Jagušić; Mirna Jurković; Dorotea Pali; Jelena Ivančić-Jelečki
Journal:  Viruses       Date:  2021-12-20       Impact factor: 5.048

6.  Hidden Viral Sequences in Public Sequencing Data and Warning for Future Emerging Diseases.

Authors:  Junna Kawasaki; Shohei Kojima; Keizo Tomonaga; Masayuki Horie
Journal:  mBio       Date:  2021-08-17       Impact factor: 7.867

7.  The Endogenous RIG-I Ligand Is Generated in Influenza A-Virus Infected Cells.

Authors:  Julia Steinberg; Timo Wadenpohl; Stephanie Jung
Journal:  Viruses       Date:  2021-08-07       Impact factor: 5.048

8.  Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells.

Authors:  Camila Metz-Zumaran; Carmon Kee; Patricio Doldan; Cuncai Guo; Megan L Stanifer; Steeve Boulant
Journal:  J Virol       Date:  2022-03-09       Impact factor: 5.103

Review 9.  Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?

Authors:  Yuguo Zhang; Bolni Marius Nagalo
Journal:  Front Immunol       Date:  2022-06-28       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.